Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

MLTX

MoonLake Immunotherapeutics

Feb 10 • 02:26PM ET

15.79

+0.04 0.23 %

Healthcare • Biotechnology • Switzerland • NASD

Peers: AMGN VRTX REGN ALNY BIIB BMRN GILD INCY SRPT BLUE

| Held by: ESML VHT SBIO ONEQ NUSC VT BBC FHLC TMED ESGV

Index	-	P/E	-	EPS (ttm)	-3.33	Insider Own	10.89%	Shs Outstand	63.70M	Perf Week	2.71%
Market Cap	1.13B	Forward P/E	-	EPS next Y	-3.59	Insider Trans	-47.00%	Shs Float	63.13M	Perf Month	-14.62%
Enterprise Value	824.31M	PEG	-	EPS next Q	-0.99	Inst Own	60.49%	Short Float	11.38%	Perf Quarter	48.51%
Income	-210.50M	P/S	-	EPS this Y	-90.31%	Inst Trans	-26.87%	Short Ratio	3.08	Perf Half Y	-70.43%
Sales	0.00M	P/B	3.48	EPS next Y	0.24%	ROA	-45.14%	Short Interest	7.18M	Perf YTD	19.78%
Book/sh	4.54	P/C	2.96	EPS next 5Y	-21.43%	ROE	-54.18%	52W High	62.75 -74.84%	Perf Year	-64.96%
Cash/sh	5.33	P/FCF	-	EPS past 3/5Y	34.85% -319.65%	ROIC	-57.97%	52W Low	5.95 165.33%	Perf 3Y	31.01%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.74% 6.93%	Perf 5Y	49.50%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-157.74%	Oper. Margin	-	ATR (14)	0.96	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.50	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	53.19	Recom	2.12
Dividend Gr. 3/5Y	- -	Current Ratio	8.50	EPS Q/Q	-95.56%	SMA20	-1.47%	Beta	1.21	Target Price	21.23
Payout	-	Debt/Eq	0.26	Sales Q/Q	-	SMA50	6.95%	Rel Volume	0.23	Prev Close	15.75
Employees	100	LT Debt/Eq	0.26	Earnings	Nov 05 BMO	SMA200	-50.70%	Avg Volume	2.33M	Price	15.79
IPO	Oct 20, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-25.17% -	Trades		Volume	410,854	Change	0.23%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-15-26	Downgrade	Goldman	Neutral → Sell	$10
Jan-09-26	Upgrade	BTIG Research	Neutral → Buy	$24
Nov-03-25	Upgrade	H.C. Wainwright	Neutral → Buy	$30
Oct-02-25	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-01-25	Downgrade	Goldman	Buy → Neutral	$7
Sep-30-25	Downgrade	Wolfe Research	Outperform → Underperform	$2
Sep-30-25	Downgrade	Citigroup	Buy → Neutral	$5
Sep-29-25	Downgrade	Stifel	Buy → Hold	$13
Sep-29-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$10
Sep-29-25	Downgrade	Jefferies	Buy → Hold	$8
Sep-29-25	Downgrade	BTIG Research	Buy → Neutral
Jul-28-25	Initiated	Rothschild & Co Redburn	Neutral	$65
May-19-25	Upgrade	Wolfe Research	Peer Perform → Outperform	$61
Mar-18-25	Initiated	RBC Capital Mkts	Outperform	$67
Jan-17-25	Upgrade	Goldman	Neutral → Buy	$62 → $82
Nov-05-24	Resumed	Wedbush	Outperform	$92 → $73
Aug-26-24	Downgrade	Wolfe Research	Outperform → Peer Perform
Jun-25-24	Initiated	Oppenheimer	Outperform	$104
Apr-02-24	Initiated	Goldman	Neutral	$62
Feb-15-24	Initiated	Wolfe Research	Outperform	$77

Show Previous Ratings

Feb-03-26 03:48PM	BioTech Breakout: MoonLake Up 30% On FDA Wins (MarketBeat)
Feb-02-26 02:25PM	Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case (Benzinga)
09:36AM	Goldman Sachs Notes VELA-2 Failure, Calls MoonLake Immunotherapeutics (MLTX) a High-Risk Play (Insider Monkey)
08:00AM	MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day (GlobeNewswire)
Jan-15-26 04:33PM	Stocks Boosted by Chip Demand Optimism (Barchart) -6.09%
06:28AM	Loading…
Jan-09-26 06:28AM	Insmeds ginormous lung drug sales; J&Js US pricing deal (BioPharma Dive) +28.94%
Jan-08-26 10:19AM	MoonLake Catapults On FDA Deal For Its Down-And-Out Skin Disease Drug (Investor's Business Daily) +27.02%
02:06PM	MoonLake Says FDA May Allow Skin Drug Filing Without New Trials, Stock Soars (Benzinga)
08:00AM	MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day (GlobeNewswire)
Dec-15-25 12:00PM	MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights MLTX (Business Wire)
Dec-11-25 08:01AM	MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX (PR Newswire)
Dec-09-25 09:00AM	Investors in MoonLake Immunotherapeutics Should Contact Levi & Korsinsky Before December 15, 2025 to Discuss Your Rights - MLTX (PR Newswire)
Dec-08-25 02:26AM	MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX (PR Newswire)
Dec-03-25 03:05PM	MoonLake's (MLTX) SLK Efficacy Claims Under Scrutiny After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority- Hagens Berman (PR Newswire) +6.63%
Dec-02-25 09:00AM	MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact Levi & Korsinsky Before December 15, 2025 to Discuss Your Rights - MLTX (PR Newswire) -5.51%
08:38PM	Loading…
Dec-01-25 08:38PM	MLTX Lawsuit: Hagens Berman Scrutinizing MoonLake's SLK Efficacy Claims After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority (PR Newswire)
03:18PM	MLTX SHAREHOLDERS: MoonLake Immunotherapeutics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 15 (Newsfile)
04:25AM	MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX (PR Newswire)
Nov-27-25 02:16PM	MoonLake Immunotherapeutics' (MLTX) Reported Phase 3 Trial Data for Sole Drug Candidate, 90% Stock Crash Triggers Investor Suit -- Hagens Berman (Newsfile)
Nov-26-25 08:50AM	MoonLake Immunotherapeutics' (MLTX) Stock Crashes 90%, Triggers Lawsuit After Reported Phase 3 Trial Data for Sole Drug Candidate -- Hagens Berman (PR Newswire)
Nov-25-25 04:31PM	MoonLake Immunotherapeutics' (MLTX) Reported Phase 3 Trial Data for Sole Drug Candidate, 90% Stock Crash Triggers Investor Suit -- Hagens Berman (PR Newswire)
Nov-21-25 08:45AM	MoonLake Immunotherapeutics Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MLTX (PR Newswire)
Nov-14-25 09:00AM	MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact Levi & Korsinsky Before December 15, 2025 to Discuss Your Rights - MLTX (PR Newswire)
Nov-11-25 04:25AM	MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX (PR Newswire) +8.60%
Nov-07-25 02:49AM	MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX (PR Newswire)
Nov-05-25 07:11AM	MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering (GlobeNewswire)
07:00AM	MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody Sonelokimab (GlobeNewswire)
Oct-29-25 08:46AM	MLTX STOCK LOSS NOTICE: MoonLake Immunotherapeutics Investors are Notified they may have been Affected by Fraud and are Urged to Contact BFA Law (Newsfile)
Oct-28-25 08:55AM	Investors in MoonLake Immunotherapeutics (MLTX): Protect Your Rights - Contact Levi & Korsinsky Before December 15, 2025 (Newsfile)
Oct-22-25 05:47PM	The Best AI for Picking Stocks, Ranked by Performance (MarketBeat)
03:14AM	Loading…
Oct-16-25 03:14AM	MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX (PR Newswire) -5.16%
Oct-15-25 03:41PM	MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights MLTX (Business Wire)
Oct-14-25 12:03PM	MoonLake Immunotherapeutics (MLTX) Faces Investor Scrutiny After Reporting Disappointing Phase 3 Trial Data For Lead Drug Candidate -- Hagens Berman (PR Newswire)
Oct-01-25 08:12AM	MoonLake Immunotherapeutics (MLTX) Faces Investor Scrutiny After Reporting Disappointing Phase 3 Trial Data For Lead Drug Candidate -- Hagens Berman (PR Newswire)
Sep-29-25 05:30PM	Podcast: U.S. Stocks Tick Higher as Government Shutdown Looms (The Wall Street Journal) -89.93% +14.81%
11:46AM	Applovin, furniture stocks, MoonLake: Trending Tickers (Yahoo Finance Video)
09:42AM	UCB Soars to Record as Rival MoonLake Crashes on Trial Data (Bloomberg)
09:38AM	MoonLake Crashes 89% On Mixed Results For Skin Disease Treatment (Investor's Business Daily)
08:40AM	MoonLake Immunotherapeutics Stock Collapses. Why It's Down 88%. (Barrons.com)
Sep-28-25 12:04PM	MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody sonelokimab (GlobeNewswire)
Sep-10-25 12:59AM	Leerink Partners Reiterated a Buy on MoonLake Immunotherapeutics (MLTX) (Insider Monkey)
Aug-27-25 03:32AM	2 Small-Cap Biotech Stocks Well Positioned for a Breakout (Motley Fool)
Aug-16-25 10:41PM	MoonLake Immunotherapeutics (MLTX): A Bull Case Theory (Insider Monkey)
Aug-05-25 07:00AM	MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update (GlobeNewswire)
Jul-31-25 12:33PM	Phase 3 Trials Accelerate MoonLake Advances for Immunologic Disease Treatment (Insider Monkey)
Jul-09-25 01:09AM	Merck nears about $10 billion deal for London-based lung therapy firm Verona, FT reports (Reuters)
Jun-04-25 12:06PM	MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout (Zacks) +5.15%
Jun-03-25 09:33AM	Constellation and Meta, Merck, Snowflake: Trending Tickers (Yahoo Finance Video) +17.95%
09:32AM	MoonLake Immunotherapeutics Catapults On Rumored Merck Takeover (Investor's Business Daily)
09:27AM	MoonLake Immunotherapeutics Catapults On Rumored $3 Billion Merck Takeover Bid (Investor's Business Daily)
07:38AM	Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report (Benzinga)
07:20AM	MoonLake Stock Jumps 23%. Why a $3 Billion Merck Offer Could Be a Win-Win. (Barrons.com)
Jun-02-25 05:08PM	Merck held talks to buy biotech MoonLake for over $3 billion, FT reports (Reuters) +5.51%
May-27-25 03:33PM	H.C. Wainwright Maintains Buy Rating on MoonLake Immunotherapeutics (MLXT), Keeps PT (Insider Monkey)
May-15-25 09:55AM	Wall Street Analysts Think MOONLAKE IMMUNO (MLTX) Could Surge 106.62%: Read This Before Placing a Bet (Zacks)
May-12-25 04:00PM	MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update (GlobeNewswire)
Apr-25-25 04:05PM	MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 (GlobeNewswire)
Apr-23-25 12:52PM	Is MoonLake Immunotherapeutics (MLTX) Among the Best Guru Stocks to Buy According to Wall Street Analysts? (Insider Monkey)
Apr-08-25 03:31AM	MoonLake Immunotherapeutics: A Buy At Dips (Seeking Alpha) -5.59%
Apr-03-25 07:00AM	MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates (GlobeNewswire)
Feb-26-25 07:00AM	MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Feb-25-25 09:49AM	Is MoonLake Immunotherapeutics (MLTX) An Oversold Biotech Stock to Buy Now? (Insider Monkey)
Feb-23-25 01:33PM	MoonLake Immunotherapeutics (MLTX): the Most Oversold Pharma Stock to Buy According to Analysts (Insider Monkey)
Feb-20-25 12:12PM	MoonLake Immunotherapeutics (MLTX): Among the Most Oversold Healthcare Stocks to Buy Now (Insider Monkey)
Jan-10-25 07:15AM	MoonLake Immunotherapeutics price target raised to $81 from $71 at BTIG (TipRanks)
Jan-08-25 07:00AM	MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody sonelokimab (GlobeNewswire)
Nov-13-24 08:00AM	MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody sonelokimab in patients with active psoriatic arthritis (GlobeNewswire)
Nov-07-24 07:00AM	MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Oct-08-24 09:11PM	Biotechnology Value Fund L.P. Reduces Stake in MoonLake Immunotherapeutics (GuruFocus.com)
Sep-24-24 11:55PM	Is MoonLake Immunotherapeutics (MLTX) the Best Guru Stock To Buy Now? (Insider Monkey) -6.36%
Sep-23-24 02:44AM	MoonLake Immunotherapeutics (MLTX): Short Seller Sentiment is Bearish On This ADR Stock (Insider Monkey)
Sep-09-24 07:00AM	MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11 (GlobeNewswire)
Aug-27-24 08:21PM	MoonLake Immunotherapeutics (MLTX): One of Oppenheimers Top Stock Picks For the Next 12 Months (Insider Monkey)
Aug-07-24 08:00AM	MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11 (GlobeNewswire)
Jun-10-24 08:00AM	MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody sonelokimab in Psoriatic Arthritis (GlobeNewswire)
May-16-24 08:00AM	MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (GlobeNewswire)
May-07-24 09:02PM	MoonLake Immunotherapeutics Reports Q1 2024 Financial Outcomes (GuruFocus.com)
01:53PM	MLTX Stock Earnings: MoonLake Misses EPS for Q1 2024 (InvestorPlace)
10:15AM	MoonLake Immunotherapeutics Q1 Net Loss Widens (MT Newswires)
08:00AM	MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Apr-10-24 07:00AM	MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions (GlobeNewswire)
Mar-11-24 04:25PM	MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test (Investor's Business Daily)
Mar-10-24 12:00PM	MoonLake announces significant improvements with Nanobody sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day (GlobeNewswire)
Mar-04-24 08:00AM	MoonLake Immunotherapeutics to present MIRA trial data of Nanobody sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024 (GlobeNewswire)
Mar-01-24 12:38AM	Insider Sell: CEO Santos da Silva Jorge Sells 123,615 Shares of MoonLake Immunotherapeutics (MLTX) (GuruFocus.com) +5.56%
Feb-29-24 08:00AM	MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10 (GlobeNewswire) -15.09%
Feb-26-24 08:00AM	MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody sonelokimab (SLK) in Hidradenitis Suppurativa (HS) (GlobeNewswire)
Feb-20-24 11:44PM	Insider Sell: CEO Santos da Silva Jorge Sells 60,000 Shares of MoonLake Immunotherapeutics (GuruFocus.com) -7.88%
Jan-11-24 09:55AM	Wall Street Analysts Believe MoonLake Immunotherapeutics (MLTX) Could Rally 26.97%: Here's is How to Trade (Zacks)
Jan-10-24 08:42AM	Is MoonLake Immunotherapeutics (MLTX) Stock a Solid Choice Right Now? (Zacks)
Dec-22-23 03:01PM	CFO Matthias Bodenstedt Sells 100,000 Shares of MoonLake Immunotherapeutics (GuruFocus.com)
Nov-14-23 12:13PM	MoonLake Immunotherapeutics (MLTX) Posts Q3 2023 Results: Clinical Progress Amid Controlled Expenses (GuruFocus.com)
08:00AM	MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Nov-06-23 04:03PM	Why Former Highflier MoonLake Plummeted 29% After A Recent Run (Investor's Business Daily) -29.11% +15.98%
09:46AM	Top-Rated MoonLake Stock Crashes On Mixed Test Results For Arthritis Drug (Investor's Business Daily)
Nov-05-23 11:00AM	MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody sonelokimab in active psoriatic arthritis (GlobeNewswire)
Oct-26-23 10:33AM	12 Best Performing NASDAQ Stocks in 2023 (Insider Monkey)
Oct-20-23 01:22PM	12 Best Performing Biotech Stocks in 2023 (Insider Monkey)
Oct-16-23 04:30PM	MoonLake Immunotherapeutics' Lead Skin Disorder Candidate Continues to Deliver on Best-Efficacy Profile: Analyst (Benzinga) +10.72% -5.20%
04:04PM	Why Top-Notch MoonLake Surged 11% And Almost Broke Out (Investor's Business Daily)

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Santos da Silva Jorge	Chief Executive Officer	Dec 08 '25	Sale	15.08	130,000	1,960,400	2,948,577	Dec 10 04:29 PM
Santos da Silva Jorge	Chief Executive Officer	Dec 09 '25	Sale	14.49	70,000	1,014,300	2,878,577	Dec 10 04:29 PM
Reich Kristian	Chief Scientific Officer	Dec 08 '25	Sale	15.08	130,000	1,960,400	72,908	Dec 10 04:29 PM
Reich Kristian	Chief Scientific Officer	Dec 09 '25	Sale	14.43	72,908	1,052,062	0	Dec 10 04:29 PM
Jorge Pedro Santos Radeck Da S	Officer	Dec 08 '25	Proposed Sale	14.90	200,000	2,980,000		Dec 08 10:36 AM
Kristian Dieter Johannes Reich	Officer	Dec 08 '25	Proposed Sale	14.80	202,908	3,003,038		Dec 08 10:07 AM
Bodenstedt Matthias	Chief Financial Officer	Oct 08 '25	Buy	9.09	10,870	98,808	627,536	Oct 09 09:01 AM
Chen Bihua	Former 10% Owner	Sep 29 '25	Sale	7.21	6,494,151	46,827,628	2,000,000	Oct 01 05:22 PM
Chen Bihua	Former 10% Owner	Sep 30 '25	Sale	6.96	5,827	40,556	1,994,173	Oct 01 05:22 PM
Moukheibir Catherine	Director	Jul 03 '25	Option Exercise	0.00	23,500	0	23,500	Jul 07 04:03 PM
Moukheibir Catherine	Director	Jul 03 '25	Sale	48.79	23,500	1,146,565	0	Jul 07 04:03 PM
Moukheibir Catherine	Director	Jul 03 '25	Proposed Sale	48.79	23,500	1,146,595		Jul 03 01:23 PM

IRWD Ironwood Pharmaceuticals Inc daily Stock Chart

Peers: ABBV VRTX ALNY GILD INCY NBIX REGN BIIB BMY EXEL

| Held by: IWM FNDA VTI IWO IBB XBI VXF SCHA VTWO FESM

Index	RUT	P/E	30.09	EPS (ttm)	0.15	Insider Own	3.68%	Shs Outstand	162.68M	Perf Week	-3.01%
Market Cap	755.74M	Forward P/E	5.32	EPS next Y	0.87	Insider Trans	-0.90%	Shs Float	156.69M	Perf Month	14.42%
Enterprise Value	1.21B	PEG	-	EPS next Q	-0.07	Inst Own	91.89%	Short Float	5.75%	Perf Quarter	141.96%
Income	29.48M	P/S	2.23	EPS this Y	1066.67%	Inst Trans	1.33%	Short Ratio	1.99	Perf Half Y	455.49%
Sales	338.99M	P/B	-	EPS next Y	648.57%	ROA	7.51%	Short Interest	9.01M	Perf YTD	37.85%
Book/sh	-1.62	P/C	5.38	EPS next 5Y	-	ROE	-	52W High	5.78 -19.63%	Perf Year	173.27%
Cash/sh	0.86	P/FCF	11.17	EPS past 3/5Y	-88.04% -47.49%	ROIC	22.45%	52W Low	0.53 781.35%	Perf 3Y	-59.25%
Dividend Est.	-	EV/EBITDA	8.23	Sales past 3/5Y	-5.30% -3.89%	Gross Margin	99.44%	Volatility	7.23% 7.75%	Perf 5Y	-54.98%
Dividend TTM	-	EV/Sales	3.58	EPS Y/Y TTM	1236.48%	Oper. Margin	42.92%	ATR (14)	0.35	Perf 10Y	-37.36%
Dividend Ex-Date	-	Quick Ratio	1.13	Sales Y/Y TTM	-10.42%	Profit Margin	8.70%	RSI (14)	52.76	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	1.13	EPS Q/Q	906.14%	SMA20	-3.50%	Beta	0.19	Target Price	8.43
Payout	0.00%	Debt/Eq	-	Sales Q/Q	33.26%	SMA50	13.20%	Rel Volume	0.38	Prev Close	4.84
Employees	253	LT Debt/Eq	-	Earnings	Nov 10 BMO	SMA200	138.06%	Avg Volume	4.52M	Price	4.65
IPO	Feb 03, 2010	Option/Short	Yes / Yes	EPS/Sales Surpr.	117.60% 63.38%	Trades		Volume	1,311,281	Change	-4.02%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-05-26	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform	$8
Apr-15-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-15-25	Downgrade	Jefferies	Buy → Hold
Apr-14-25	Downgrade	Citizens JMP	Mkt Outperform → Mkt Perform
Sep-09-24	Initiated	Leerink Partners	Market Perform	$5
Aug-08-24	Downgrade	CapitalOne	Overweight → Equal Weight	$12 → $4
Jan-17-24	Initiated	Craig Hallum	Buy	$21
Dec-14-23	Initiated	Wells Fargo	Overweight	$20
Nov-09-23	Initiated	Jefferies	Buy	$21
Sep-28-23	Initiated	JMP Securities	Mkt Outperform	$22
Sep-02-22	Initiated	CapitalOne	Overweight	$15
Apr-22-22	Initiated	Piper Sandler	Overweight	$16
Sep-30-20	Downgrade	Wells Fargo	Overweight → Equal Weight	$14 → $9
Jun-17-20	Initiated	Northland Capital	Outperform	$14
Jul-10-19	Resumed	Credit Suisse	Neutral
Mar-27-19	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Feb-25-19	Upgrade	H.C. Wainwright	Sell → Neutral	$14
Jan-24-19	Upgrade	JP Morgan	Underweight → Neutral
Nov-07-18	Downgrade	JP Morgan	Neutral → Underweight
Nov-07-18	Downgrade	Credit Suisse	Outperform → Neutral

Show Previous Ratings

Feb-08-26 08:28AM	3 Stocks Trading Near $5 With Massive Earnings Upside (MarketBeat)
Feb-05-26 08:48AM	Does Ironwood's Bullish 2026 View Signal Greater Linzess Adoption? (Zacks)
Feb-04-26 09:06AM	Craig-Hallum Bullish on Ironwood Pharmaceuticals (IRWD), Keeps Buy Rating (Insider Monkey) -6.37%
Jan-26-26 02:11AM	Zacks.com featured highlights include IPG Photonics, Ironwood and Science Applications (Zacks)
Jan-23-26 10:33AM	4 Stocks Trading Near 52-Week High With More Upside Potential (Zacks)
09:36AM	Loading…
Jan-08-26 09:36AM	Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics (Zacks)
Jan-07-26 03:25PM	Ironwood Pharmaceuticals' 2026 Guidance Shock Sparks a Major Re-Rating (MarketBeat) -5.12%
08:45AM	5 Small Drug Stocks to Buy as Industry Recovery Picks Up (Zacks)
Jan-05-26 10:28AM	Ironwood Stock Rises 27% on Upbeat Revenue Guidance for 2026 (Zacks) +7.49%
Jan-03-26 07:20AM	Ironwood backs FY25 revenue view $290M-$310M, consensus $306.97M (TipRanks)
07:20AM	Ironwood sees FY26 revenue $450M-$475M, consensus $319.47M (TipRanks)
Jan-02-26 12:21PM	Ironwood Pharmaceuticals Stock Soars as Drug-Price Cut Boosts Prospects for 2026 (Barrons.com) +26.71%
07:05AM	Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance (Business Wire)
Dec-10-25 11:30AM	Why Is Ironwood (IRWD) Up 24.9% Since Last Earnings Report? (Zacks)
Nov-28-25 10:11AM	Ironwood (IRWD) Skyrockets 23% as Govt Price for Linzess Falls Within Expectations (Insider Monkey) -9.33%
11:58AM	Loading…
Nov-27-25 11:58AM	IRWD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Pick? (Zacks)
Nov-21-25 10:30AM	Can Linzess Continue to Aid IRWD's Top Line After a Strong Q3? (Zacks)
Nov-13-25 10:36AM	IRWD Rises 110% in a Month: Should You Buy, Sell or Hold the Stock? (Zacks) +8.36%
Nov-11-25 09:56AM	IRWD Beats on Q3 Earnings & Revenues, Raises 2025 View, Stock Soars (Zacks) +14.23%
Nov-10-25 08:25AM	Ironwood Pharmaceuticals (IRWD) Q3 Earnings and Revenues Surpass Estimates (Zacks) +31.77%
07:21AM	Ironwood: Q3 Earnings Snapshot (Associated Press Finance)
07:05AM	Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance (Business Wire)
Nov-06-25 07:35AM	Former blockbuster Linzess grows label with paediatric IBS-C approval (Pharmaceutical Technology)
Nov-05-25 05:35PM	Xencor (XNCR) Reports Q3 Loss, Misses Revenue Estimates (Zacks) +10.16%
Oct-20-25 09:15AM	Xeris Biopharma Holdings, Inc. (XERS) Hit a 52 Week High, Can the Run Continue? (Zacks) +7.69%
Oct-16-25 07:56AM	BioCryst (BCRX) Soars 6.1%: Is Further Upside Left in the Stock? (Zacks)
Oct-15-25 09:17AM	Teladoc Health Expands Clarity Platform With Workplace Safety Tool (Zacks) +8.78%
06:19AM	Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics (Zacks)
Oct-14-25 10:57AM	5 Small Drug Stocks to Buy as the Industry Shows Some Recovery (Zacks)
09:50AM	Why Ironwood Pharmaceuticals (IRWD) is a Top Momentum Stock for the Long-Term (Zacks)
09:50AM	Loading…
Sep-22-25 09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Aug-21-25 09:50AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio (Zacks) +7.27%
Aug-08-25 10:36AM	IRWD Stock Rises as Q2 Earnings & Revenues Trump Estimates (Zacks)
Aug-07-25 08:25AM	Ironwood Pharmaceuticals (IRWD) Beats Q2 Earnings and Revenue Estimates (Zacks) +9.32%
07:26AM	Ironwood: Q2 Earnings Snapshot (Associated Press Finance)
07:05AM	Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance (Business Wire)
Jun-06-25 11:31AM	Why Is Ironwood (IRWD) Down 18.4% Since Last Earnings Report? (Zacks) +6.58%
May-08-25 09:55AM	IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates (Zacks) -11.63%
May-07-25 08:20AM	Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -14.55%
07:26AM	Ironwood: Q1 Earnings Snapshot (Associated Press Finance)
07:05AM	Ironwood Pharmaceuticals Reports First Quarter 2025 Results (Business Wire)
May-06-25 10:00AM	Vivos Therapeutics, Inc. (VVOS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
May-05-25 07:15AM	Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-03-25 10:24PM	The 1-Minute Market Report May 4, 2025 (Seeking Alpha)
May-01-25 10:01AM	Analysts Estimate Ironwood Pharmaceuticals (IRWD) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-30-25 04:25PM	Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference (Business Wire)
Apr-28-25 10:25AM	The 1-Minute Market Report April 27, 2025 (Seeking Alpha) +9.23%
Apr-25-25 07:05AM	Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance (Business Wire)
Apr-22-25 04:05PM	Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support (Business Wire) +7.66%
Apr-16-25 01:07PM	Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News (Zacks)
Apr-15-25 09:18AM	Ironwood Shares Tank on Regulatory Update for Apraglutide (Zacks) +11.47%
07:12AM	Ironwoods shares sink as FDA demands new trial for lead drug (Pharmaceutical Technology)
Apr-14-25 07:00AM	Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide (Business Wire) -31.48%
Apr-13-25 10:44AM	The 1-Minute Market Report April 13, 2025 (Seeking Alpha)
Apr-10-25 10:49AM	Ironwood Pharmaceuticals: Setting A Strong Foundation For A Return To Growth (Seeking Alpha)
09:25AM	Why Ironwood Pharmaceuticals Inc. (IRWD) Went Down On Thursday? (Insider Monkey)
Apr-01-25 10:28AM	Corcept (CORT) Stock Jumps 109.1%: Will It Continue to Soar? (Zacks)
Mar-31-25 08:05AM	The 1-Minute Market Report March 30, 2025 (Seeking Alpha)
Mar-27-25 04:05PM	Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing (Business Wire)
Mar-25-25 11:08AM	Catalyst (CPRX) Surges 6.2%: Is This an Indication of Further Gains? (Zacks)
Mar-02-25 12:24PM	Is Ironwood Pharmaceuticals, Inc. (IRWD) the Best Small Cap Pharma Stock to Buy Now? (Insider Monkey)
Feb-28-25 02:14AM	Ironwood Pharmaceuticals Inc (IRWD) Q4 2024 Earnings Call Highlights: Strong Prescription ... (GuruFocus.com)
Feb-27-25 11:20PM	Q4 2024 Ironwood Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -5.26%
08:15AM	Ironwood Pharmaceuticals (IRWD) Q4 Earnings and Revenues Miss Estimates (Zacks)
07:20AM	Ironwood: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance (Business Wire)
Feb-26-25 08:13AM	Ironwood Pharmaceuticals Inc (IRWD) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Feb-20-25 04:00PM	Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call (Business Wire)
Feb-05-25 06:28PM	Millrose Properties Set to Join S&P SmallCap 600 (PR Newswire) -8.06%
Jan-29-25 04:05PM	Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future (Business Wire) -38.17%
Jan-18-25 08:20AM	Ozempic, Xtandi among next 15 drugs selected for U.S. price talks (TipRanks)
Dec-20-24 09:15AM	Heres Why Brown Capital Management Small Company Fund Sold Ironwood Pharmaceuticals (IRWD) (Insider Monkey) +14.69%
Nov-26-24 04:01PM	Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference (Business Wire) +5.07%
Nov-13-24 04:01PM	Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference (Business Wire)
Nov-08-24 04:01AM	Ironwood Pharmaceuticals Inc (IRWD) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ... (GuruFocus.com) +6.44%
Nov-07-24 08:15AM	Ironwood Pharmaceuticals (IRWD) Misses Q3 Earnings Estimates (Zacks) -7.54%
07:20AM	Ironwood: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Ironwood Pharmaceuticals Reports Third Quarter 2024 Results (Business Wire)
Nov-06-24 07:29AM	Ironwood Pharmaceuticals Inc (IRWD) Q3 2024 Earnings Report Preview: What To Expect (GuruFocus.com) +12.25%
Oct-28-24 07:00AM	Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024 (Business Wire)
Oct-24-24 04:00PM	Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call (Business Wire)
Oct-16-24 01:06PM	State Street Corp's Strategic Acquisition of Ironwood Pharmaceuticals Shares (GuruFocus.com)
08:58AM	Is Ironwood Pharmaceuticals, Inc. (IRWD) the Penny Stock with the Biggest Upside Potential According to Analysts? (Insider Monkey)
Oct-09-24 05:36PM	Ironwood Pharmaceuticals Inc (IRWD) Q2 2024 Earnings Call Highlights: Strong LINZESS Demand ... (GuruFocus.com)
Sep-17-24 08:40AM	Implied Volatility Surging for Ironwood (IRWD) Stock Options (Zacks)
Sep-01-24 10:26PM	Ironwood Pharmaceuticals, Inc. (IRWD): The Best Multibagger Penny Stock of 2025? (Insider Monkey)
Aug-29-24 08:41PM	10 Best Multibagger Penny Stocks of 2025 (Insider Monkey) +7.58%
04:01PM	Ironwood Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference (Business Wire)
Aug-09-24 10:56AM	Ironwood (IRWD) Q2 Earnings & Revenues Fall Shy of Estimates (Zacks)
Aug-08-24 08:15AM	Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q2 (Zacks) -32.61%
07:16AM	Ironwood: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Ironwood Pharmaceuticals Reports Second Quarter 2024 Results (Business Wire)
Aug-01-24 10:01AM	Earnings Preview: Ironwood Pharmaceuticals (IRWD) Q2 Earnings Expected to Decline (Zacks)
Jul-25-24 04:00PM	Ironwood Pharmaceuticals to Host Second Quarter 2024 Investor Update Call (Business Wire)
Jul-17-24 08:30AM	Implied Volatility Surging for Ironwood Pharmaceuticals (IRWD) Stock Options (Zacks)
Jul-08-24 07:00AM	Memo Therapeutics AG appoints Paul Carter as Chairperson (GlobeNewswire)
Jun-12-24 07:00PM	Insider Sale: Director Julie Mchugh Sells Shares of Ironwood Pharmaceuticals Inc (IRWD) (GuruFocus.com) -6.27%
Jun-10-24 07:00PM	Insider Sale: Director Catherine Moukheibir Sells 80,000 Shares of Ironwood Pharmaceuticals Inc ... (GuruFocus.com)
May-30-24 04:01PM	Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference (Business Wire)
May-21-24 06:00AM	Ironwood Late-Breaker Oral Presentation at Digestive Disease Week Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF) (Business Wire) +5.61%

Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. It operates through the Human Therapeutics segment. The company was founded on January 5, 1998 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Silver Ronald	Principal Accounting Officer	Jan 05 '26	Sale	4.60	35,416	162,914	276,809	Jan 07 04:05 PM
RONALD SILVER	Officer	Jan 05 '26	Proposed Sale	4.27	35,416	151,226		Jan 05 04:41 PM
Gaskins Tammi L	Chief Commercial Officer	Nov 17 '25	Sale	3.32	6,016	19,973	235,264	Nov 19 04:05 PM
Gaskins Tammi L	Officer	Nov 17 '25	Proposed Sale	3.37	6,324	21,312		Nov 14 04:05 PM
Gaskins Tammi L	Chief Commercial Officer	Aug 11 '25	Sale	0.84	1,316	1,105	241,280	Aug 13 04:05 PM
John Minardo	Chief Legal Officer	Aug 11 '25	Sale	0.84	7,754	6,513	400,378	Aug 13 04:05 PM
Martini Gregory S.	Chief Financial Officer	Aug 11 '25	Sale	0.84	1,265	1,063	182,545	Aug 13 04:05 PM
Silver Ronald	Principal Accounting Officer	Aug 11 '25	Sale	0.84	2,846	2,391	276,809	Aug 13 04:05 PM
John Minardo	Officer	Aug 11 '25	Proposed Sale	0.88	8,281	7,287		Aug 08 04:10 PM
Martini Gregory S.	Officer	Aug 11 '25	Proposed Sale	0.88	1,351	1,189		Aug 08 04:09 PM
Gaskins Tammi L	Officer	Aug 11 '25	Proposed Sale	0.88	1,406	1,237		Aug 08 04:08 PM
MCCOURT Thomas A	Chief Executive Officer	May 16 '25	Sale	0.58	13,353	7,745	1,147,281	May 20 04:14 PM
Gaskins Tammi L	Chief Commercial Officer	May 16 '25	Sale	0.58	2,563	1,487	242,596	May 20 04:10 PM
MCCOURT Thomas A	Officer	May 19 '25	Proposed Sale	0.59	14,661	8,650		May 16 04:07 PM
Gaskins Tammi L	Officer	May 19 '25	Proposed Sale	0.59	2,814	1,660		May 16 04:05 PM

MLTX

MoonLake Immunotherapeutics

IRWD

Ironwood Pharmaceuticals Inc

Upgrade your FINVIZ experience